136 related articles for article (PubMed ID: 38869019)
21. Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data.
Danese S; Tran J; D'Haens G; Rubin DT; Aoyama N; Zhou W; Ilo D; Yao X; Sanchez Gonzalez Y; Panaccione R
Inflamm Bowel Dis; 2023 Nov; 29(11):1723-1729. PubMed ID: 36790041
[TBL] [Abstract][Full Text] [Related]
22. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.
Papp K; Warren RB; Green L; Reich K; Langley RG; Paul C; Asahina A; Johnson L; Arora V; Osuntokun O; Lebwohl M
Lancet Rheumatol; 2023 Sep; 5(9):e542-e552. PubMed ID: 38251498
[TBL] [Abstract][Full Text] [Related]
24. Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
Chiorean M; Daperno M; Lees CW; Bonfanti G; Soudis D; Modesto I; Deuring JJ; Edwards RA
Adv Ther; 2023 Oct; 40(10):4440-4459. PubMed ID: 37525075
[TBL] [Abstract][Full Text] [Related]
25. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036
[TBL] [Abstract][Full Text] [Related]
26. Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study.
Steere B; Schmitz J; Powell N; Higgs R; Gottlieb K; Liu Y; Jia B; Tuttle JL; Sandborn WJ; Sands BE; D'Haens G; Reinisch W; Krishnan V
Clin Transl Gastroenterol; 2023 Jul; 14(7):e00578. PubMed ID: 36881820
[TBL] [Abstract][Full Text] [Related]
27. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.
D'Haens G; Baert F; Danese S; Kobayashi T; Loftus EV; Sandborn WJ; Dornic Q; Lindner D; Kisfalvi K; Marins EG; Vermeire S
Eur J Gastroenterol Hepatol; 2024 Apr; 36(4):404-415. PubMed ID: 38417060
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
Blauvelt A; Kimball AB; Augustin M; Okubo Y; Witte MM; Capriles CR; Sontag A; Arora V; Osuntokun O; Strober B
Br J Dermatol; 2022 Dec; 187(6):866-877. PubMed ID: 35791755
[TBL] [Abstract][Full Text] [Related]
30. Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries.
Armuzzi A; Hart A; Cappelleri JC; Mammar N; Hur P; Hoskin B; Hennessy F; Milligan G; Dignass A
BMC Gastroenterol; 2023 Jan; 23(1):17. PubMed ID: 36658481
[TBL] [Abstract][Full Text] [Related]
31. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.
Helwig U; Mross M; Schubert S; Hartmann H; Brandes A; Stein D; Kempf C; Knop J; Campbell-Hill S; Ehehalt R
BMC Gastroenterol; 2020 Jul; 20(1):211. PubMed ID: 32640990
[TBL] [Abstract][Full Text] [Related]
32. Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.
Loftus EV; Colombel JF; Takeuchi K; Gao X; Panaccione R; Danese S; Dubinsky M; Schreiber S; Ilo D; Finney-Hayward T; Zhou W; Phillips C; Gonzalez YS; Shu L; Yao X; Zhou Q; Vermeire S
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2347-2358.e6. PubMed ID: 36464141
[TBL] [Abstract][Full Text] [Related]
33. Mirikizumab: First Approval.
Keam SJ
Drugs; 2023 Jul; 83(11):1045-1052. PubMed ID: 37389706
[TBL] [Abstract][Full Text] [Related]
34. Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.
Colombel JF; Schreiber S; D'Haens G; Rizzo J; Kligys K; Griffith J; Zambrano J; Zhou Q; Zhang Y; Kalabic J; Rieder F; Dubinsky MC; Panaccione R
J Crohns Colitis; 2024 Jun; 18(6):818-827. PubMed ID: 38069472
[TBL] [Abstract][Full Text] [Related]
35. Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFα-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial.
Nagahori M; Watanabe K; Motoya S; Ogata H; Kanai T; Matsui T; Suzuki Y; Pinton P; Ursos L; Sakamoto S; Shikamura M; Hori T; Fernandez J; Hibi T; Watanabe M
Digestion; 2021; 102(5):742-752. PubMed ID: 33454706
[TBL] [Abstract][Full Text] [Related]
36. Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial.
Danese S; Ferrante M; Feagan BG; Peyrin-Biroulet L; Hibi T; Sandborn WJ; Schreiber S; Ritter T; Loftus EV; Rogler G; Oortwijn A; Yun C; Le Brun FO; Dinoso J; Hsieh J; Vermeire S
Am J Gastroenterol; 2023 Jan; 118(1):138-147. PubMed ID: 36113491
[TBL] [Abstract][Full Text] [Related]
37. The impact of biological interventions for ulcerative colitis on health-related quality of life.
LeBlanc K; Mosli MH; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
[TBL] [Abstract][Full Text] [Related]
38. Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.
Deodhar A; Shiff NJ; Gong C; Chan EKH; Hsia EC; Lo KH; Akawung A; Kim L; Xu S; Reveille JD
Rheumatol Ther; 2023 Aug; 10(4):983-999. PubMed ID: 37322274
[TBL] [Abstract][Full Text] [Related]
39. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.
Hanauer S; Panaccione R; Danese S; Cheifetz A; Reinisch W; Higgins PDR; Woodworth DA; Zhang H; Friedman GS; Lawendy N; Quirk D; Nduaka CI; Su C
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):139-147. PubMed ID: 30012431
[TBL] [Abstract][Full Text] [Related]
40. A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark
Gastroenterol Hepatol (N Y); 2019 May; 15(5 Suppl 2):1-24. PubMed ID: 31632213
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
